|
| Mechanism of Tangwang Mingmu Granules in treating diabetic retinopathy based on network pharmacology and molecular docking |
| Hits 808 Download times 1665 Received:October 12, 2022 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2023.01.18 |
| Key Words
Tangwang Mingmu Granule;diabetic retinopathy;network pharmacology;molecular docking;disease-target network |
| Author Name | Affiliation | E-mail | | WANG Fang | Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | WANG Yucheng | Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | ODURO Patrick Kwabena | Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | TONG Wanyu | Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | LENG Ling | Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
State Key Laboratory of Component-Based Chinese Medicine, Tianjin 301617, China | | | LI Ruiqiao | Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
State Key Laboratory of Component-Based Chinese Medicine, Tianjin 301617, China | | | WANG Qilong | Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
State Key Laboratory of Component-Based Chinese Medicine, Tianjin 301617, China | wangqilong_00@tjutcm.edu.cn | | LIU Erwei | Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
State Key Laboratory of Component-Based Chinese Medicine, Tianjin 301617, China | liuwei628@hotmail.com |
|
| Abstract
|
| [Objective] The potential molecular mechanism of Tangwang Mingmu Granules in the treatment of diabetic retinopathy (DR) was studied by network pharmacology and molecular docking technology,to provide an experimental basis for the development of new drugs of Tangwang Mingmu Granules for the prevention and treatment of DR.[Methods] The chemical composition information of the drugs comprising Tangwang Mingmu Granules was retrieved on Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). The active component target database and DR target gene database were established via PharmMapper server,Disgenet and GeneCards databases,and target matching was performed to obtain the drug-disease common target. Subsequently,the PPI network diagram was constructed,and the core targets were screened,and the traditional Chinese medicine-active ingredient-core target network diagram was constructed. GO and KEGG enrichment analyses for drug-disease common targets were performed using R-4.1.1. Finally,molecular docking analysis was performed using Auto Dock software,and the results were visualized using Pymol and Discovery Studio software. On this basis,the above results were verified by in vitro cell experiments.[Results] In this study,62 common targets of Tangwang Mingmu Granules-DR were screened. The 226 items were identified by GO enrichment analysis,and 163 signaling pathways were identified by KEGG pathway enrichment screening,including AGE-RAGE signaling pathway,TNF signaling pathway,FoxO signaling pathway and other pathways in diabetic complications. Molecular docking results showed that the active components of Tangwang Mingmu Granules,such as luteolin,epicatechin and arachidonic acid,could form relatively stable molecular binding with target proteins,such as BMP2,EGFR and FN1. In human retinoblastoma cell Y79 induced by high glucose,Tangwang Mingmu Granules can inhibit the protein expression of EGFR and MAPK14.[Conclusion] In this study,the mechanism of Tangwang Mingmu Granules in the treatment of DR was preliminarily explored,and the results showed that Tangwang Mingmu Granules had the characteristics of multi-components,multi-targets,and multi-pathway synergy in the treatment of DR,which would provide guidance and part of the basis for further research and development. |
|
|
|
|
|
|
|
